Biothera to Present at BIO-Europe Spring 2009
EAGAN, MN – March 13, 2009 – Biothera will discuss its technology and clinical development program for its targeted immunotherapeutic drug at 12:30 pm on Wednesday, March 18 at BIO-Europe Spring 2009 in Milan, Italy.
BIO-Europe Spring is one of the word's leading biotechnology partnering conferences. The 2009 conference will host more than 950 companies and feature approximately 150 company presentations.
Biothera is a privately held biotechnology company that is in Phase II clinical development with Imprime PGG®, a novel drug that works synergistically with monoclonal antibodies through specific innate immune cell activation. This therapy’s unique mechanism of action has broad implications for treating a most types of cancers.
Biothera is currently conducting a dual-arm Phase II clinical trial in metastatic colorectal cancer and two Phase II trials in non small cell lung cancer (NSCLC).
Contact:
David Walsh
VP, Communications
Biothera, the Immune Health Company
651-256-4606